ASCO 2024 | Innovative TIL Therapy OBX-115 Offers New Hope for ICI-Resistant Melanoma Patients

ASCO 2024 | Innovative TIL Therapy OBX-115 Offers New Hope for ICI-Resistant Melanoma Patients

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, Eastern Time. One study on OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) therapy, garnered widespread attention. This research focuses on patients with immune checkpoint inhibitor (ICI)-resistant metastatic melanoma. Unlike traditional TIL therapy, OBX-115 has a key advantage: it does not require high-dose interleukin-2 (IL-2) systemic treatment, reducing the toxicity risk for patients. Initial results indicate that OBX-115 performs well in both safety and efficacy, providing new hope for ICI-resistant melanoma patients.
ASCO 2024 | Advances in Uveal Melanoma Treatment

ASCO 2024 | Advances in Uveal Melanoma Treatment

Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.
Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients

Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients

Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.
ASCO 2024丨Professor Zengjun Li: SHR-A1912 Phase I Study Results First Unveiled, Pioneering a New Chapter in B-NHL Treatment

ASCO 2024丨Professor Zengjun Li: SHR-A1912 Phase I Study Results First Unveiled, Pioneering a New Chapter in B-NHL Treatment

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was grandly held in Chicago from May 31 to June 4. At this conference, Chinese researchers presented the first results of the Phase I study of SHR-A1912 in patients with B-cell non-Hodgkin lymphoma (B-NHL) on the international stage, including preliminary key data from the dose-escalation (D-ESC) and dose-expansion (D-EXP) phases. To promote the standardization of lymphoma diagnosis and treatment in China, Hematology Frontier invited the principal investigator of this study, Professor Zengjun Li from Shandong Cancer Hospital, to deeply analyze the study’s highlights and discuss future trends in the field of lymphoma treatment.
Professor Ying Wang: The Advantages and Prospects of CN201 in Treating Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia (R/R B-ALL)

Professor Ying Wang: The Advantages and Prospects of CN201 in Treating Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia (R/R B-ALL)

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting took place in Chicago, USA, from May 31 to June 4. The ASCO Annual Meeting gathers oncology experts, doctors, and researchers from around the world to share the latest research findings, discuss cutting-edge diagnostic and therapeutic techniques, and advance the field of oncology. A study by Professor Jianxiang Wang and Professor Ying Wang's team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, was selected for an oral presentation (Abstract 6505) at the conference. The study explores the therapeutic application of the CD3×CD19 bispecific antibody CN201 in relapsed/refractory adult acute B-cell lymphoblastic leukemia (R/R B-ALL), showing promising treatment prospects. "Oncology Frontier - Hematology Frontier" invited Professor Ying Wang for an interview to discuss this study and the treatment of R/R B-ALL.
ASCO & EHA Special丨Professor Jun Zhu: Opportunities and Challenges for Chinese Original Anticancer Drugs on the International Stage

ASCO & EHA Special丨Professor Jun Zhu: Opportunities and Challenges for Chinese Original Anticancer Drugs on the International Stage

As summer begins, the sun shines warmly and everything thrives. In this vibrant season, two major international events in the pharmaceutical world—the American Society of Clinical Oncology (ASCO 2024) and the European Hematology Association (EHA 2024) annual meetings—are about to take place. These meetings are not only platforms for showcasing global pharmaceutical innovations but also important venues for domestic and international oncology and hematology experts to exchange ideas and spark insights. On the eve of these events, Oncology Frontier - Hematology Frontier invited Professor Jun Zhu from Peking University Cancer Hospital to discuss "Chinese Original Drugs on the International Stage: Opportunities and Challenges." Under Professor Zhu's guidance, we will review the achievements of Chinese anticancer drugs in lymphoma treatment, examine the gaps with international standards, and look ahead to future developments. Through continuous learning, innovation, and international cooperation, Chinese anticancer drug research and development (R&D) will reach new heights, bringing hope to cancer patients and contributing to the dream of a Healthy China with Chinese wisdom and strength.
Professor Man Li:  From Uncertainty to Definitive Evidence—PostMONARCH Study Proves the Benefit of Cross-Line Treatment with CDK4/6 Inhibitors| Man Talks Breast Cancer: ASCO Special

Professor Man Li:  From Uncertainty to Definitive Evidence—PostMONARCH Study Proves the Benefit of Cross-Line Treatment with CDK4/6 Inhibitors| Man Talks Breast Cancer: ASCO Special

In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.
EASL Special New Voices丨Latest Advances in ACLF: Transition from ACLF to Pre-ACLF

EASL Special New Voices丨Latest Advances in ACLF: Transition from ACLF to Pre-ACLF

From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy. This event brought together over 7,000 liver disease specialists from around the world. On the third day of the conference, "Hepatology Digest" invited Dr. Wenyi Gu, a protégé of Professors Jonel Trebicka from University Hospital Münster and Hai Li from Renji Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, to share her insights on two exciting studies presented at this year's Milan EASL conference and her takeaways from the event.
EASL China Voice: Professor Liang Peng’s Team Reveals Key Mechanism of Pyroptosis in Hepatocytes Mediating ACLF Liver Injury

EASL China Voice: Professor Liang Peng’s Team Reveals Key Mechanism of Pyroptosis in Hepatocytes Mediating ACLF Liver Injury

From June 5 to 8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was successfully held in Milan, Italy. During the conference, Professor Liang Peng's team from the Third Affiliated Hospital ,Sun Yat-sen University unveiled the significant link between hepatocyte pyroptosis and acute-on-chronic liver failure (ACLF). The research found that IL-1β released from pyroptotic hepatocytes activates the IL1R1/MyD88/TBK1 pathway in neutrophils, promoting the formation of neutrophil extracellular traps (NETs) and exacerbating liver injury. Through bioinformatics analysis, mouse model experiments, and clinical patient data validation, the team confirmed this mechanism and identified IL-1R1 and MyD88 as potential therapeutic targets for ACLF. This discovery provides new perspectives and strategies for the treatment of ACLF.
EASL2024 Interview | Dr. Terry Yip: Prognostic significance of a change in liver stiffness measurement in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

EASL2024 Interview | Dr. Terry Yip: Prognostic significance of a change in liver stiffness measurement in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

With the rapid development of modern medical technology, non-invasive assessment methods have attracted more and more attention. In the field of metabolically associated fatty liver disease (MAFLD), liver hardness measurement (LSM) has become an important indicator for non-invasive assessment of liver-related events. At the annual meeting of the European Association for the Study of the Liver (EASL) this year, Dr.Terry Yip of the Chinese University of Hong Kong presented an exciting research result, which explored the prognostic significance of liver hardness measurement in patients with MAFLD through a large-scale international collaborative study. The study provides a new perspective for clinicians and patients, revealing the great potential of non-invasive assessment in the management of liver disease.